SMARCA2 and cancer: Importantly, the development of therapeutic strategies to target aberrant residual SWI/SNF complex warrants consideration since some SMARCA4-mutant cancers, such as SCCOHTs and a subset of non-small-cell lung carcinomas, lack expression of SMARCA2 and can, therefore, grow in the absence of both ATPase subunits [45].